Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05228899Phase 1Completed

Zofin to Treat COVID-19 Long Haulers

Role: lead

NCT04384445Phase 1Completed

Zofin (Organicell Flow) for Patients With COVID-19

Role: lead

NCT05643729Phase 1Suspended

Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)

Role: lead

NCT04657406Unknown

Expanded Access to Zofin for Patients With COVID-19

Role: lead

All 4 trials loaded